{"product_id":"fda-adverse-event-reports-on-daybue-trofinetide-and-nuplazid-pimavanserin-from-january-1-2023","title":"FDA Adverse Event Reports on DAYBUE (trofinetide) and Nuplazid (pimavanserin) from January 1, 2023","description":"\u003cb\u003eOriginal Request:\u003c\/b\u003e Please provide the full detailed adverse events reports on DAYBUE (trofinetide) and Nuplazid (pimavanserin). Time period: January 1, 2023 to date request is fulfilled. Thank you.\u003cbr\u003eTags: Pharma, Adverse Event, 2023","brand":"FDA","offers":[{"title":"Default Title","offer_id":50901561409700,"sku":"FDAFT1433","price":89.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/foiadocs.com\/products\/fda-adverse-event-reports-on-daybue-trofinetide-and-nuplazid-pimavanserin-from-january-1-2023","provider":"FOIA Document Source","version":"1.0","type":"link"}